The effects of cytochrome P450 induction by xenobiotics on endobiotic metabolism in pre-clinical safety studies

Toxicology Mechanisms and Methods

Volumn 20, Issue 4, 2010, Pages 159-166

  Amacher, David E ^a  

^a DABT   (United States)

Author keywords

Cardiovascular effects; Fatty acid metabolism; Steroid metabolism; Vitamin metabolism; Xenoreceptors

Indexed keywords

CYTOCHROME P450; XENOBIOTIC AGENT;

BIOSYNTHESIS; ENZYME INDUCTION; REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; XENOBIOTICS;

EID: 77955293411     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376511003690307     Document Type: Review

References (63)

1. Aboutabl ME, Zordoky BN, El-Kadi AO. 2009. 3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. Br J Pharmacol 158:1808-1819.
2. Antoun J, Goulitquer S, Amet Y, Dreano Y, Salaun JP, Corcos L, Plée-Gautier E. 2008. CYP4F3B is induced by PGA1 in human liver cells: A regulation of the 20-HETE synthesis. J Lipid Res 49:2135-2141.
3. Bain DL, Heneghan AF, Connaghan-Jones KD, Miura MT. 2007. Nuclear receptor structure: Implications for function. Annu Rev Physiol 69:201-220. (Pubitemid 46457641)
4. Bertz RJ, Granneman GR. 1997. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258. (Pubitemid 27122521)
5. Cheng JW, Frishman WH, Aronow WS. 2009. Updates on cytochrome P450-mediated cardiovascular drug interactions. Am J Ther 16:155-163.
6. Comer CP, Chengelis CP, Levin S, Kotsonis FN. 1985. Changes in thyroidal function and liver UDP-glucuronosyltransferase activity in rats following administration of a novel imidazole (SC-37211). Toxicol Appl Pharmacol 80:427-436. (Pubitemid 15225515)
7. Davies TS, Monro A. 1995. Marketed human pharmaceuticals reported to be tumorigenic in rodents. J Am Coll Toxicol 14:90-107.
8. Evans WE, Relling MV. 1999. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286:487-491.
9. Fielden MR, Brennan R, Gollub J. 2007. A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol Sci 99:90-100. (Pubitemid 47250370)
10. Froy O. 2009. Cytochrome P450 and the biological clock in mammals. Curr Drug Metab 10:104-115.
11. Gnerre C, Blättler S, Kaufmann MR, Looser R, Meyer UA. 2004. Regulation of CYP3A4 by the bile acid receptor FXR: Evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 14:635-645. (Pubitemid 39411263)
12. Gnerre C, Schuster GU, Roth A, Handschin C, Johansson L, Looser R, Parini P, Podvinec M, Robertsson K, Gustafsson JA, Meyer UA. 2005. LXR deficiency and cholesterol feeding affect the expression and phenobarbital-mediated induction of cytochromes P450 in mouse liver. J Lipid Res 46:1633-1642. (Pubitemid 41099330)
13. Gu YZ, Hogenesch JB, Bradfield CA. 2000. The PAS superfamily: Sensors of environmental and developmental signals. Ann Rev Pharmacol Toxicol 40:519-561. (Pubitemid 30340692)
14. Guengerich FP. 2001. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611-650. (Pubitemid 32565712)
15. Handschin C, Meyer UA. 2003. Induction of drug metabolism: The role of nuclear receptors. Pharmacol Rev 55:649-673. (Pubitemid 37504978)
16. Hardeland R, Pandi-Perumal SR, Cardinali DP. 2006. Melatonin. Int J Biochem Cell Biol 38:313-316. (Pubitemid 41821880)
17. Hardwick JP. 2008. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem Pharmacol 75:2263-2275.
18. Haschek WM, Rousseaux CG. 1998. Fundamentals of toxicologic pathology. San Diego, CA: Academic Press.
19. Hayes JD, Dinkova-Kostova AT, McMahon M. 2009. Cross-talk between transcription factors AhR and Nrf2: Lessons for cancer chemoprevention from dioxin. Toxicol Sci 111:199-201.
20. Hewitt NJ, Lecluyse EL, Ferguson SS. 2007. Induction of hepatic cytochrome P450 enzymes: Methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 37:1196-1224. (Pubitemid 350035534)
21. Hirose Y, Nagahori H, Yamada T, Deguchi Y, Tomigahara Y, Nishioka K, Uwagawa S, Kawamura S, Isobe N, Lake BG, Okuno Y. 2009. Comparison of the effects of the synthetic pyrethroid metofluthrin and phenobarbital on CYP2B form induction and replicative DNA synthesis in cultured rat and human hepatocytes. Toxicology 258:64-69.
22. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. 2006. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 34:1756-1763. (Pubitemid 44427479)
23. Juberg DR, Mudra DR, Hazelton GA, Parkinson A. 2006. The effect of fenbuconazole on cell proliferation and enzyme induction in the liver of female CD1 mice. Toxicol Appl Pharmacol 214:178-187.
24. Kakizaki S, Yamazaki Y, Takizawa D, Negishi M. 2008. New insights on the xenobiotic-sensing nuclear receptors in liver diseases-CAR and PXR. Curr Drug Metab 9:614-621.
25. Kitchin KT, Brown JL, Kulkarni AP. 1992. Predictive assay for rodent carcinogenicity using in vivo biochemical parameters: Operational characteristics and complementarity. Mutat Res 266:253-272.
26. Kodama S, Koike C, Negishi M, Yamamoto Y. 2004. Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol Cell Biol 24:7931-7940. (Pubitemid 39167443)
27. Konno Y, Neigishi M, Kodama S. 2008. The roles of nuclear receptors CAR and PXR in hepatic energy metabolism. Drug Metab Pharmacokinet 23:8-13.
28. Lane CS, Wang Y, Betts R, Griffiths WJ, Patterson LH. 2007. Comparative cytochrome P450 proteomics in the livers of immune-deficient mice using 18O stable isotope labeling. Mol Cell Proteomics 6:953-962. (Pubitemid 47019397)
29. Lee MD, Ayanoglu E, Gong L. 2006. Drug-induced changes in P450 enzyme expression at the gene expression level: A new dimension to the analysis of drug-drug interactions. Xenobiotics 36:1013-1080. (Pubitemid 44844112)
30. Lim YP, Huang JD. 2008. Interplay of pregnane X receptor with other nuclear receptors on gene regulation. Drug Metab Pharmacokinet 23:14-21.
31. Lundell K, Wikvall K. 2008. Species-specific and age-dependent bile acid composition: Aspects on CYP8B and CYP4A subfamilies in bile acid biosynthesis. Curr Drug Metab 9:323-331. (Pubitemid 351836421)
32. Luoma PV. 2008. Cytochrome P450 and gene activation-from pharmacology to cholesterol elimination and regression of atherosclerosis. Eur J Clin Pharmacol. 64:841-850.
33. Luoma PV, Sotaniemi EA, Pelkonen RO, Arranto A, Ehnholm C. 1982. Plasma high-density lipoproteins and hepatic microsomal enzyme induction. Relation to histological changes in the liver. Eur J Clin Pharmacol 23:275-282. (Pubitemid 12028468)
34. Ma X, Idle JR, Krausz KW, Gonzalez FJ. 2005. Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos 33:489-494. (Pubitemid 40393190)
35. Martignoni M, Groothius GMM, de Kanter R. 2006. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-994.
36. Matsunawa M, Amano Y, Endo K, Uno S, Sakaki T, Yamada S, Makishima M. 2009. The aryl hydrocarbon receptor activator benzo[a]pyrene enhances vitamin D3 catabolism in macrophages. Toxicol Sci 109:50-58.
37. McClain RM. 1989. The significance of hepatic microsomal enzyme induction and altered thyroid function in rats: Implications for thyroid gland neoplasia. Toxicol Pathol 17:294-306. (Pubitemid 19218939)
38. Meyer zu Schwabedissen HE, Kim RB. 2009. Hepatic OATP1B transporters and nuclear receptors PXR and CAR: Interplay, regulation of drug disposition genes, and single nucleotide polymorphisms. Mol Pharm 6:1644-1661.
39. Mikamo E, Harada S, Nishikawa J, Nishihara T. 2003. Endocrine disruptors induce cytochrome P450 by affecting transcriptional regulation via pregnane X receptor. Toxicol Appl Pharmacol 193:66-72. (Pubitemid 37373766)
40. Mise M, Hashizume T, Komuro S. 2008. Characterization of substrate specificity of dog CYP1A2 using CYP1A2-deficient and wild-type dog liver microsomes. Drug Metab Dispos 36:1903-1908.
41. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW. 2004. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1-18. (Pubitemid 38183957)
42. Niwa T, Murayama N, Yamazaki H. 2009. Oxidation of endobiotics mediated by xenobiotic-metabolizing forms of human cytochrome P450. Curr Drug Metab (in press).
43. Opie LH. 2003. Cardiovascular drug interactions: In: Frishman WH, Sonnenblick EH, Sica DA, editors. Cardiovascular pharmacotherapeutics. 2nd ed. New York: McGraw Hill. pp 875-891.
44. Price RJ, Walters DG, Finch JM, Gabriel KL, Capen CC, Osimitz TG, Lake BG. 2007. A mode of action for induction of liver tumors by Pyrethrins in the rat. Toxicol Appl Pharmacol 218:186-95. (Pubitemid 46188473)
45. Roth A, Looser R, Kaufmann M, Blättler SM, Rencurel F, Huang W, Moore DD, Meyer UA. 2008a. Regulatory cross-talk between drug metabolism and lipid homeostasis: Constitutive androstane receptor and pregnane X receptor increase Insig-1 expression. Mol Pharmacol 73:1282-1289. (Pubitemid 351439210)
46. Roth A, Looser R, Kaufmann M, Meyer UA. 2008b. Sterol regulatory element binding protein 1 interacts with pregnane X receptor and constitutive androstane receptor and represses their target gene. Pharmacogenet Genomics 18:325-337. (Pubitemid 351367526)
47. Rüegg J, Penttinen-Damdimopoulou P, Mäkelä S, Pongratz I, Gustafsson JA. 2009. Receptors mediating toxicity and their involvement in endocrine disruption. EXS 99:289-323.
48. Tay S, Dickmann L, Dixit V, Isoherranen N. 2009 A comparison of the role of PPAR and RAR on CYP26 regulation. Mol Pharmacol. 77:218-227.
49. Thomas H, Dollenmeier P, Persohn E, Weideli H, Waechter F. 1995. Antitoxicants and light stabilizers: Toxic effects of 3, 5-di-alkyl-4-hydroxy- phenyl propionic acid derivatives in the rat and their relevance for human safety evaluation. In: Thomas H, Hess R, Waechter F, editors. Toxicology of industrial compounds. London: Taylor & Francis. pp 319-339.
50. Thum T, Borlak J. 2000. Cytochrome P450 mono-oxygenase gene expression and protein activity in cultures of adult cardiomyocytes of the rat. Br J Pharmacol 130:1745-1752. (Pubitemid 30655785)
51. Urquhart BL, Tirona RG, Kim RB. 2007. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: Implications for interindividual variability in response to drugs. J Clin Pharmacol 47:566-578. (Pubitemid 46632158)
52. Waechter F, Beilstein P, Burger AG, O'Connell M, Fabreguettes C, Forster R, Weideli H. 1999. Subchronic toxicity study with ethylene-bis-(oxyethylene)- bis-(3-tert-butyl-4-hydroxy-5-methylhydro cin namate) in the cynomolgus monkey: Lack of stimulation of the pituitary-thyroid-liver axis. Toxicol Sci 51:36-43. (Pubitemid 29439228)
53. Wang B, Zhou SF. 2009. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem 16:4066-4218.
54. Wang JF, Yang Y, Sullivan MF, Min J, Cai J, Zeldin DC, Xiao YF, Morgan JP. 2002. Induction of cardiac cytochrome p450 in cocaine-treated mice. Exp Biol Med 227:182-188.
55. Wang Y, Al-Gazzar A, Seibert C, Sharif A, Lane C, Griffiths WJ. 2006. Proteomic analysis of cytochromes P450: A mass spectrometry approach. Biochem Soc Trans 34:1246-1251. (Pubitemid 46769031)
56. Waxman DJ. 1999. P450 gene induction by structurally diverse xenochemicals: Central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 369:11-23. (Pubitemid 29434534)
57. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE. 2004. Drug-drug interactions for UDPglucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208. (Pubitemid 39410902)
58. Wu KM, Farrelly JG. 2006. Preclinical development of new drugs that enhance thyroid hormone metabolism and clearance: Inadequacy of using rats as an animal model for predicting human risks in an IND and NDA. Am J Ther 13:141-144.
59. You L. 2004. Steroid hormone biotransformation and xenobiotic induction of hepatic steroid metabolizing enzymes. Chem Biol Interact 147:233-246. (Pubitemid 38591494)
60. Zordoky BN, Aboutabl ME, El-Kadi AO. 2008. Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol-induced cardiac hypertrophy in rats. Drug Metab Dispos 36:2277-2286.
61. Zordoky BN, Anwar-Mohamed A, Aboutabl ME, El-Kadi AO. 2010. Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats. Toxicol Appl Pharmacol 242:38-46.
62. Zordoky BN, El-Kadi AO. 2008. Induction of several cytochrome P450 genes by doxorubicin in H9c2 cells. Vascul Pharmacol 49:166-172.
63. Zordoky BN, El-Kadi AO. 2009. Role of NF-kappaB in the regulation of cytochrome P450 enzymes. Curr Drug Metab 10:164-178.